Literature DB >> 7119135

Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients.

C B Schaffer, A Shahid, J I Javaid, M W Dysken, J M Davis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7119135

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  9 in total

1.  Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.

Authors:  W H Chang; Y W Lam; M W Jann; H Chen
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 3.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

Review 4.  Haloperidol dosing strategies in the treatment of delirium in the critically ill.

Authors:  Erica H Z Wang; Vincent H Mabasa; Gabriel W Loh; Mary H H Ensom
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

Review 5.  Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Authors:  A Cario Altamura; Francesca Sassella; Annalisa Santini; Clauno Montresor; Sara Fumagalli; Emanuela Mundo
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Pharmacological management of agitation in emergency settings.

Authors:  A Yildiz; G S Sachs; A Turgay
Journal:  Emerg Med J       Date:  2003-07       Impact factor: 2.740

Review 7.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

8.  Population pharmacokinetics of haloperidol in terminally ill adult patients.

Authors:  L G Franken; R A A Mathot; A D Masman; F P M Baar; D Tibboel; T van Gelder; B C P Koch; B C M de Winter
Journal:  Eur J Clin Pharmacol       Date:  2017-07-05       Impact factor: 2.953

9.  A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia.

Authors:  Hidenobu Suzuki; Keishi Gen
Journal:  Neuropsychiatr Dis Treat       Date:  2013-08-28       Impact factor: 2.570
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.